BRAFV600E

Overview

BRAFV600E refers to the valine-to-glutamic acid substitution at codon 600 in the BRAF gene, a well-characterized activating mutation in the BRAF serine/threonine kinase. This alteration is a canonical oncogenic driver that constitutively activates the MAPK pathway, promoting cell proliferation and survival in multiple tumor types. Because of its strong biological effect and prevalence in several cancers, BRAFV600E is widely used as a molecular target in precision oncology.

Clinically, BRAFV600E is most often discussed in the context of melanoma, thyroid cancer, and central nervous system tumors, where it can define treatment selection and resistance patterns. Targeted inhibition of BRAFV600E, often in combination with downstream MEK inhibition, has become an important therapeutic strategy. The mutation is also relevant to cancer immunotherapy sequencing, because tumors harboring BRAFV600E may be treated with BRAF/MEK inhibitors, checkpoint inhibitor, or both depending on disease context and prior therapy.

Focus of Latest Publications

Recent publications on BRAFV600E have focused heavily on treatment response, resistance mechanisms, and molecular monitoring in aggressive thyroid cancer and melanoma, with additional work in central nervous system tumors. In anaplastic thyroid carcinoma, investigators examined the role of liquid biopsy for assessing and monitoring BRAFV600E status in relapsed/metastatic disease, highlighting the clinical need for noninvasive molecular assessment in a setting where targeted therapy is available but disease behavior remains poorly defined. Other thyroid cancer studies explored how BRAFV600E-driven tumors respond to MAPK pathway inhibition and why resistance emerges after dabrafenib plus trametinib therapy.

Several studies addressed resistance biology in BRAFV600E-mutant thyroid cancer and melanoma. Multi-omic profiling of anaplastic thyroid cancer samples from patients receiving type I RAF inhibitor and MEK inhibitor therapy suggested that acquired resistance is associated with MAPK pathway reactivation and immunosuppressive macrophage proliferation. The same study found that the type II RAF inhibitor naporafenib was highly active in ATC cell lines and that naporafenib plus trametinib could overcome both innate and acquired resistance in cell lines and patient-derived xenograft models, although compensatory MAST1 mutations were identified as a mechanism of resistance to naporafenib. In a separate thyroid cancer study, the ETV5/p38 signaling axis was linked to BRAFV600E-associated aggressiveness, and p38 inhibition combined with dabrafenib showed strong synergy in vitro, including in cells resistant to dabrafenib and trametinib with an acquired TP53 mutation.

Other work examined BRAFV600E-targeted therapy beyond thyroid cancer. In melanoma, ICMT inhibition was shown to suppress BRAFV600E-mutant tumor cell proliferation and invasion, reduce xenograft and mouse tumor growth, and inhibit growth of BRAF-inhibitor-resistant cells; this effect was tied to an ICMT-INPP5E axis that supports BRAFV600E-driven tumor growth. Another melanoma study described a complex resistance trajectory to vemurafenib in SkMel28 cells, with early senescence-like and differentiation-associated changes followed by restoration of MAPK-ERK signaling and renewed proliferation. A case series in BRAF V600E-mutant melanoma of unknown primary with brain metastases reported rapid hyperacute intracranial deterioration after switching from BRAF/MEK inhibition to ipilimumab/nivolumab, particularly in patients with elevated L-lactate dehydrogenase, underscoring the importance of therapeutic sequencing in cancer immunotherapy.

BRAFV600E has also been studied in central nervous system tumors, where dabrafenib plus trametinib was evaluated in patients with progressive or recurrent BRAFV600E-mutated CNS tumors through the Drug Rediscovery Protocol. Collectively, these publications emphasize the continued clinical relevance of BRAFV600E as a therapeutic target, while also showing that durable benefit is limited by adaptive resistance, pathway reactivation, and context-specific treatment challenges.

Key Publications

• NEWJun Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center. (Endocrine, 2026, PMID 42334691): "Approximately 40% of ATCs harbor the BRAFV600E mutation, for which targeted therapy is available."
• Jun Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer. (Cell reports. Medicine, 2026, PMID 42143022): "Although patients with the BRAFV600E alteration respond to the type I RAF inhibitor (RAFi) dabrafenib with trametinib, most rapidly develop adaptive or acquired resistance."
• May ICMT supports BRAFV600E-driven tumor growth by membrane targeting of the CAAX protein INPP5E. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42127111): "Although ICMT has been pursued to disrupt RAS membrane targeting, its role in BRAFV600E-driven cancers and critical substrates remains unclear."
• Apr Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series. (Melanoma research, 2026, PMID 41941611): "...BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series."
• May BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41830662): "Dual MAPK pathway inhibition with dabrafenib and trametinib has demonstrated significant activity across several BRAFV600E-mutated tumor types."
• May Resistance of BRAFV600E-mutant melanoma to Vemurafenib: a senescence-induced swing from differentiation to blastulation followed by proliferation. (Cancer letters, 2026, PMID 41831518): "Resistance to Vemurafenib (VEM), a targeted BRAFV600E inhibitor, was examined in the metastatic paratetraploid (XX, abnormal Y chromosome) melanoma cell line, SkMel28."
• May Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. (Molecular cancer therapeutics, 2026, PMID 41544239): "Around 25% of PDTCs and 35% of ATCs carry the BRAFV600E mutation, which constitutively activates the MAPK pathway, a key driver of cell growth."